Below is a list of the treatments we currently offer via our Innovative Medicines Division. Visit Sandoz and Advanced Accelerator Applications to learn about our generics and radiopharmaceutical ...
PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...
Prozkoumejte pracovní příležitosti ve společnosti Novartis v seznamu níže. Pro další pozice ve společnosti Novartis Gene Therapies (dříve AveXis) navštivte GTx Hledání práce. Oncology Sales Specialist ...
The five-year invasive disease-free survival (iDFS) rates were 85.5% in the Kisqali plus ET arm versus 81.0% in the ET alone arm, representing a clinically meaningful 4.5% improvement 1. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback